“Medigene AG’s JOVI Technology Receives U.S. Patent Grant: Expanding the Company’s Patent Portfolio”
Medigene AG Receives U.S. Patent for JOVI Technology Planegg/Martinsried, February 19, 2025 Medigene AG Medigene AG, a leading oncology platform company dedicated to the research and development of T cell receptor (TCR)-guided therapies for cancer treatment, has announced the issuance of a patent by the U.S. Patent Office for its JOVI technology. This innovative method…